

BIOSIGN ANNOUNCES INTENTION TO DELIVER NON-INVASIVE HEALTHCARE MONITORING SOLUTION WITH MITEL

TORONTO, ONTARIO, Wednesday, November 10, 2010 – Biosign Technologies Inc. (TSXV: BIO), a novel health monitoring technology company, has announced the intention to deliver its non-invasive healthcare monitoring solution in collaboration with Mitel (NASDAQ: MITL), a leading provider of unified communications software solutions. The companies have signed a memorandum of understanding to collaborate on a solution intended to enable certain Mitel products to be used as a voice and data communication portal between a patient, a resident, or an employee using the Biosign UFIT® PAD to send their vital data to Biosign's data mining and rendering servers, and then have results sent to the appropriate parties

"Utilizing a single non-invasive device for data collection, a single platform, and a universal virtual network is an extremely powerful combination that customers can seamlessly adopt and deliver across their organization - locally, regionally, nationally, or globally," says Radu Leca, President & CEO, Biosign Technologies. "We look forward to working with Mitel to develop a solution aligned with the needs of customers."

The combined solution is intended to help prevent adverse responses to medication, track chronic illnesses such as Diabetes and Hypertension, provide medication reminders and management, and offer remote patient management.

Key markets that could be addressed with a combined solution include assisted living and long term care facilities, workplace wellness programs and people living at home that require chronic disease management tools to assist them in their daily living activities.

Contact Information for Biosign

Alan S. Roemer, SVP
The Trout Group LLC
Phone: 646 378-2900
Email : aroemer@troutgroup.com

Radu Leca, President & CEO
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234
Email: ceo@biosign.com

Contact Information for Mitel

Danielle McNeil, Public Relations
Mitel
Phone: (800) 267-6244 x4643
Email: danielle_mcneil@mitel.com

About Biosign Technologies Inc.

Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com.

About Mitel Networks Corporation

Mitel Networks (Nasdaq: MITL) is a global provider of business communications solutions and services, consisting of unified communications and collaboration software applications, IP telephony platforms, mobility applications and managed and network services. Mitel enables businesses of all sizes to move beyond basic fixed telephony tools toward integrated multi-media collaboration solutions, accessible from anywhere, helping to improve performance, gain competitive advantage, and reduce costs. Mitel's global headquarters are in Ottawa, Canada, US headquarters are in Chandler, Arizona and EMEA headquarters are in Caldicot, UK, with offices, partners, and resellers worldwide. For more information visit: <http://www.mitel.com>

Mitel and the Mitel logo are registered trademarks of Mitel Networks Corporation. All other trademarks are the property of their respective owners.

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).

“Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”